MetLife Investment Management’s CTI BioPharma Corp. (DE) Common Stock CTIC Stock Holding History

MetLife Investment Management’s Portfolio CTIC Stock Details CTIC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-48,688	Closed	-$204K	–	3036
2023 Q1	$204K	Hold	48,688	–	–	﹤0.01%	2210
2022 Q4	$293K	Hold	48,688	–	–	﹤0.01%	2006
2022 Q3	$283K	Hold	48,688	–	–	﹤0.01%	2062
2022 Q2	$291K	Buy	+48,688	New	+$249K	﹤0.01%	2044
2018 Q3	–	Sell	-27,473	Closed	-$137K	–	2675
2018 Q2	$137K	Buy	+27,473	New	+$120K	﹤0.01%	2103

Other funds holding CTIC

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return

MetLife Investment Management's CTIC Position: Q2 2023 in Review

MetLife Investment Management sold out of CTI BioPharma Corp. (DE) Common Stock (CTIC) in Q2 2023, closing a stake of 48,688 shares — an estimated $204K sold.

MetLife Investment Management first reported a position in CTIC in Q2 2018 and held it in 5 quarters. The position peaked at $293K in Q4 2022. 2 funds tracked by Wall St. Rank hold CTIC as of Q2 2023.

MetLife Investment Management reported no remaining CTI BioPharma Corp. (DE) Common Stock position as of Q2 2023 after selling out during the quarter.
MetLife Investment Management sold 48,688 CTI BioPharma Corp. (DE) Common Stock shares in Q2 2023, an estimated $204K.
MetLife Investment Management first reported a position in CTI BioPharma Corp. (DE) Common Stock in Q2 2018 and held it in 5 quarters.
MetLife Investment Management's CTI BioPharma Corp. (DE) Common Stock position peaked at $293K in Q4 2022.
2 funds tracked by Wall St. Rank held CTI BioPharma Corp. (DE) Common Stock as of Q2 2023.

Based on MetLife Investment Management's 13F filing for Q2 2023, filed 10 Aug 2023.